Free Trial
→ Read this warning immediately (From Porter & Company) (Ad)tc pixel
NASDAQ:CNTN

Hillstream Biopharma 5/13/2026 Earnings Report

Hillstream Biopharma logo
$3.51 +0.24 (+7.34%)
Closing price 05/13/2026 04:00 PM Eastern
Extended Trading
$3.58 +0.07 (+2.11%)
As of 04:50 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Hillstream Biopharma EPS Results

Actual EPS
-$0.23
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Hillstream Biopharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Hillstream Biopharma Announcement Details

Quarter
Date
5/13/2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Hillstream Biopharma Earnings Headlines

Canton Strategic Holdings Reports First Quarter 2026 Financial and Operational Results
May 13 at 8:15 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/canton-strategic-holdings-reports-first-quarter-2026-financial-and-operational-results-302770829.html
Hillstream Biopharma (CNTN) vs. Its Peers Financial Analysis
May 12 at 3:37 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30773092
Before you buy SpaceX shares, consider this alternative approach
SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history. But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered.tc pixel
 |  Weiss Ratings (Ad)
Financial Survey: Hillstream Biopharma (CNTN) and Its Rivals
May 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30761429
Canton Strategic Holdings, Inc. Presents Quarterly Canton Network Ecosystem Update
April 20, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/canton-strategic-holdings-inc-presents-quarterly-canton-network-ecosystem-update-302747263.html
Canton Strategic Holdings Reports Full Year 2025 Financial and Operational Results
March 31, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/canton-strategic-holdings-reports-full-year-2025-financial-and-operational-results-302729923.html
See More Hillstream Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Hillstream Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Hillstream Biopharma and other key companies, straight to your email.

About Hillstream Biopharma

Hillstream Biopharma (NASDAQ:CNTN), Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2019 and is based in Bridgewater, New Jersey.

View Hillstream Biopharma Profile
Earnings Tools